Taken together, these results suggest PI3KCA gain-of-function mutations may predict sensitivity to PI3K pathway inhibitors, whereas KRAS and BRAF mutations may lead to resistance in some tumor types such as colorectal cancer. Here, PIK3CD is linked to colorectal cancer.